● Olatorepatide achieved up to 19.3% body-weight loss at Week 48, with a high proportion of participants achieving clinically meaningful weight-loss.

● Olatorepatide demonstrated remarkably improved gastrointestinal tolerability with low rates of gastrointestinal adverse events and treatment discontinuation in the Phase 3 study.

SHANGHAI, China, March 7, 2026 — Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma", 3692.HK) today announced positive Phase 3 results for olatorepatide (HS-20094), an investigational once-weekly GLP-1/GIP receptor dual agonist, in adults with obesity or overweight.

The randomized, double-blind, placebo-controlled study enrolled 604 adults across 33 clinical sites and evaluated once-weekly olatorepatide versus placebo over 48 weeks. The study met its co-primary endpoints, demonstrating a statistically significant reduction in body weight from baseline at Week 48 and a statistically significantly greater proportion of participants achieving at least 5% weight loss at Week 48 with olatorepatide versus placebo. Participants treated with olatorepatide achieved up to 19.3% mean weight loss from baseline at Week 48. Responder analyses showed that up to 97.2% of participants achieved ≥5% weight loss at Week 48. These results demonstrate that a high proportion of participants achieved clinically meaningful weight-loss, with robust efficacy maintained through Week 48.

Olatorepatide demonstrated remarkably improved gastrointestinal tolerability in the study, with lower rates of gastrointestinal adverse events and treatment discontinuation relative to those reported in published Phase 3 dual incretin trials.

Detailed results from this Phase 3 study are planned to be presented at an upcoming international medical conference and submitted for publication in a peer-reviewed scientific journal.

"The clinical data for Olatorepatide is highly promising. The fact that body weight was still on a downward trajectory at 48 weeks indicates the compound's potential for deeper efficacy with long-term use," commented Principal Investigator, Department of Endocrinology, Peking University People's Hospital，Prof. Li-Nong Ji. "Furthermore, Olatorepatide demonstrated a gastrointestinal tolerability profile more favorable to that seen in other Phase 3 dual incretin studies. This improved tolerability is a significant advantage, as it may be more likely to facilitate sustained therapy and clearly differentiates olatorepatide within the dual incretin class."

“Gastrointestinal tolerability has long been a key barrier to improving patient adherence to treatment,” said Eliza Sun, Executive Director of the Board at Hansoh Pharma. “With its innovative dual-target design, olatorepatide delivers remarkable weight-loss efficacy while demonstrating improvements in gastrointestinal tolerability. The average incidence of nausea was below 10%, and the average incidence of vomiting was below 5%. We believe olatorepatide has the potential to become a more desirable treatment option for people living with overweight or obesity and this profile may help support long-term treatment adherence and provide a new treatment option for this population.”

About olatorepatide (HS-20094)

olatorepatide is an investigational once-weekly GLP-1/GIP dual receptor agonist designed to regulate metabolic pathways involved in appetite control, glucose metabolism and energy balance. By activating complementary incretin pathways, olatorepatide aims to deliver robust weight reduction while maintaining a favorable tolerability profile. Olatorepatide is currently being investigated in Phase III clinical studies for the treatment of obesity, overweight and type 2 diabetes. In June 2025, Hansoh Pharmaceutical entered into a licensing agreement with Regeneron Pharmaceuticals for olatorepatide. Under the agreement, Hansoh retains development and commercialization rights in Mainland China, Hong Kong and Macau, while Regeneron holds the rights outside these territories.

About Phase III Study Design (NCT06839664 / CTR20243973)

The Phase III randomized, double-blind, placebo-controlled, multicenter study in China evaluated the efficacy and safety of olatorepatide in adults with obesity or overweight. The study assessed four cohorts, 5mg, 10mg, 15mg and placebo treatment groups, utilizing a 1:1:1:1 randomization.

About Obesity

Obesity is a complex chronic disease driven by multiple factors. Currently, more than 650 million adults worldwide are affected, and the World Health Organization (WHO) has long recognized obesity as a major global public health epidemic requiring urgent action. According to data from 2025, the combined prevalence of overweight and obesity among adults in China has exceeded 50%^[1]. As a major risk factor for a range of chronic conditions, obesity significantly increases the risk of type 2 diabetes, cardiovascular diseases and certain cancers, posing a substantial challenge to public health.

[1] World Obesity Federation. World Obesity Atlas 2025. Overweight, obesity and non-communicable diseases. New global, regional and national estimates of the prevalence of overweight and obesity in adults from 2000 to 2030. Mar, 2025. https://s3-eu-west-1.amazonaws.com/wof-files/World_Obesity_Atlas_2025_rev1.pdf

About Hansoh Pharma

Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).

Statements

1. This announcement is intended for healthcare professionals only and not for advertising purposes.

2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.

3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.

4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.

Forward-Looking Statements

This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.

The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.

Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.

All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).